A New Review Maps the Peptides Studied for Healthy Aging

A review published this spring in Frontiers in Aging pulls something scattered into one place. It walks through nine peptides that researchers have studied for age-related decline, sorts them by which part of aging they target, and lays the evidence for each one side by side. If you've been trying to make sense of why the same handful of peptide names keep coming up in longevity conversations, this is a useful map.

It's worth being clear about what kind of paper this is, because that shapes how much weight to give it.

What the Review Actually Did

This is a narrative review, sometimes called a mini review. The authors searched the research databases (PubMed, Scopus, and regulatory records from the FDA and WADA) through January 2026, then selected 20 primary sources covering nine peptides. They didn't run a new study or test anything themselves. They gathered what's already known and organized it.

The nine peptides span very different targets: tirzepatide for metabolic health, epitalon for telomere biology, GHK-Cu for skin and collagen, BPC-157 and TB-500 for tissue repair, Semax for the brain, CJC-1295 and ipamorelin for the growth hormone axis, and bremelanotide (PT-141) for sexual desire. The authors group them by the aging pathway each one acts on, which is a genuinely helpful way to see the field.

One Caveat Up Front

A map that puts nine peptides on the same page can make them look more alike than they are. They aren't. The evidence behind them ranges from large FDA-reviewed human trials to a handful of animal studies, and the review itself says plainly that it's a scientific overview for researchers, not clinical guidance.

The single most useful thing to take from it is the split between what's approved and what isn't.

The Two With Real Approval

Tirzepatide (sold as Mounjaro and Zepbound) is the most established name on the list. It's a dual GIP and GLP-1 receptor agonist, FDA-approved for type 2 diabetes, obesity, and obstructive sleep apnea, backed by the large Phase 3 SURPASS and SURMOUNT trials. The review's angle is that its effects on weight, visceral fat, and insulin sensitivity also touch several drivers of aging, though it's approved as a treatment for specific conditions, not as an anti-aging drug.

Bremelanotide, better known as PT-141, is the other approved one, and it's directly relevant to women. The FDA approved it in 2019 for hypoactive sexual desire disorder in premenopausal women. It works through melanocortin receptors in the brain rather than on blood flow, which is what sets it apart from the more familiar men's medications.

What Midlife Women Are Actually Searching

Several of the research-only peptides in the review map closely onto what women in perimenopause and beyond tend to look into, and the paper covers each one honestly, gaps included.

GHK-Cu, the copper peptide, is studied for skin, collagen, and wound healing, and the review notes that our natural levels of it fall with age. Epithalon is the most-studied peptide for telomere biology, with rodent longevity data and a link to melatonin and sleep, though the human evidence is limited to small studies. The growth hormone peptides CJC-1295 and ipamorelin are studied for the natural decline in growth hormone that starts in your thirties, but the review is candid that a CJC-1295 trial program was discontinued and that the combination data comes from animals.

For all of these, the review's regulatory column says the same thing over and over: not approved, no long-term safety data. BPC-157 and TB-500 carry an added note that both are banned by anti-doping agencies. These are research compounds, and the paper describes them that way.

The Gaps the Authors Flag

The review is refreshingly direct about what nobody knows yet. For the non-approved peptides, it points to three recurring holes: optimal dosing regimens, what happens when peptides are combined, and reliable biomarkers to tell whether any of it is actually working. Its conclusion is that these compounds need well-designed human trials before anyone can claim they extend healthspan. That's not a knock on the science. It's an accurate description of where the science is.

What This Is, and Isn't

This is a report on a published review that organizes existing peptide research for aging. It is not new evidence that any of these peptides work, and it is not medical advice or a recommendation to use anything. Most of the peptides discussed are sold for research purposes only and are not approved for human use. The two that are approved are prescription medications, and decisions about them belong with a qualified healthcare provider who knows your history.